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Background
Fast, accurate determination of vaccine titer during
influenza vaccine manufacture is important in under-
standing process performance and correctly scaling
each process step. Traditionally Single Radial Immuno-
diffusion (SRID) assays have been used as the ‘gold
standard’ but the assay requires very skilled operators
to obtain reproducible results and is relatively low
throughput. ELISAs have also been used to determine
titer but have lower precision and dynamic range. BLI
combines the high throughput characteristics of a 96-
well plate based ELISA assay in conjunction with
improvements in accuracy and repeatability derived
from a simpler direct measurement of mass transfer
on binding.
The assay is based on the binding of the vaccine to
polyclonal antibodies that recognise the influenza epi-
topes presented by the vaccine. The polyclonal anti-
body is bound to a protein G or protein A derivatized
biosensor, depending on the animal source of the anti-
body. This configuration gives increased flexibility by
allowing swift changes between vaccines derived from
different viral strains by simply binding the paired
antibody for the new strain to a biosensor without the
need for derivatization. Hence the assay is suitable for
the rapid changes in the viral strains represented in a
vaccine. A robust assay, capable of determining vaccine
titer from various process stages has been developed.
Figure 1 illustrates coefficient of variance and binding
rate across a range of concentrations. The assay has
been shown to be applicable to both attenuated and
synthetic vaccines and is an effective test for vaccine
potency.
Materials and methods
Samples taken directly from purification steps were
assayed with zero sample clean up, having been only
diluted with a proprietary ForteBio sample buffer. Pro-
tein A and Protein G biosensors were used in the assay.
The system uses well plate technology allowing for high
sample throughput.
Results
Native samples gave an average result of 53.6 μg/mL.
The heat treated samples showed a loss of response to
an average value of 7.2 μg/mL, proving they had been
inactivated and that the assay is also a test for vaccine
potency.
Conclusions
The total analysis time was less than 3 hours on the
Octet RED96 System. The BLItz platform allowed at-
line sampling to be conducted in the process develop-
ment laboratories. A change in the vaccine strains or
formulation did not require a change in equipment or
method: only limited requalification of the assay would
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Figure 1 CVs for each standard are <7 % in the range 10-100
μg/mL R2 values for each curve were >0.97
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be required. In-process samples and purified samples
were both analysed without matrix effect issues. The
assay successfully analysed heat inactivated samples and
is therefore a test for potency.
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